Research Articles
From the Authors
"Immune correlates of clinical benefit from cancer therapies are not well established. We describe ex vivo detectable tumor antigen specific immune responses in women with metastatic breast cancer coinciding with durable complete remission after immunoendocrine therapy," said Dr. Sylvia Adams. "In this longitudinal study over two years, tumor antigen specific T cell responses were not detectable in patients with disease progression, therefore suggesting that these biomarkers may serve as a benchmark for clinical benefit."
(1).gif) |
Myeloid Derived Suppressor and Dendritic Cell Subsets are Related to Clinical Outcome in Prostate Cancer Patients Treated with Prostate GVAX and Ipilimumab
Saskia JAM Santegoets, Anita GM Stam, Sinéad M Lougheed, Helen Gall, Karin Jooss, Natalie Sacks, Kristen Hege, Israel Lowy, Rik J Scheper, Winald R Gerritsen, Alfons JM van den Eertwegh and Tanja D de Gruijl
Journal for Immunotherapy of Cancer 2014, 2:31 (16 September 2014) |
From the Authors
"In this Phase I/II study we found pre-treatment systemic rates of MDSC together with on-treatment activation of DC subsets to hold putative predictive value for clinical outcome of patients with castration resistent prostate cancer, treated with combined GVAX and ipilimumab immunotherapy," said Dr. Tanja D de Gruijl. "Unsupervised cluster analysis revealed the particularly strong predictive power of a parameter panel that also included CTLA4+ Th cell frequencies. Our findings thus suggest that directed flowcytometric profiling of key immune subsets in peripheral blood may aid in the selection of patients likely to benefit from vaccination and immune checkpoint blockade."
From the Authors
“Gamma chain cytokines play a central role in the regulation of lymphocyte development. Members of this family have demonstrated utility in numerous cancer immunotherapy strategies, particularly those that target co-stimulatory receptors on T cells," said. Dr. Michael J. McNamara. "This study profiled the direct response of freshly antigen-activated CD8+ T cells to different gc cytokines, with a particular focus on the expression of TNFR family receptors. The observations reported here will serve as a valuable reference point to assist the rational development of combinatorial cancer immunotherapies.”
From the Authors
"Interleukin-2 (IL2) remains the only therapy to produce 20+ year complete remissions in patients with stage IV melanoma and renal cell cancer," said Dr. Janice P. Dutcher. "It should continue to be the first treatment option for these patients if they are eligible. As described in this article, guidelines in 2014 for the screening and management of IL2 therapy have become more flexible and easier to translate into clinical practice, as well as providing increased safety. This paper provides a guide for treating physicians who want to provide the best possible options for patients with advanced melanoma and renal cell cancer."
August Highly Accessed Articles
 A Pilot Study of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination Combined with Sunitinib for Metastatic Renal Cell Carcinoma
Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y et al. Journal for ImmunoTherapy of Cancer 2014, 2:30 (19 August 2014)
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF et al. Journal for ImmunoTherapy of Cancer 2014, 2:25 (19 August 2014)
Submit your Research to JITC!
SITC Members and non-members alike are invited to submit manuscripts to the Society's official journal.
Categories
- Basic Tumor Immunology
- Case Reports
- Clinical/Translational Cancer Immunotherapy
- Immunotherapy Biomarkers
- Reviews/Editorials
JITC Editor-in-Chief
Pedro J. Romero, MD - Ludwig Center for Cancer Research
Section Editors
Cornelis J.M. Melief, MD, PhD - ISA Therapeutics BV
F. Stephen Hodi, Jr., MD - Dana-Farber Cancer Institute
Walter J. Urba, MD, PhD - Earle A. Chiles Research Institute
Lisa H. Butterfield, PhD - University of Pittsburgh Cancer Institute
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
Thomas F. Gajewski, MD, PhD - University of Chicago
To view the full editorial board, please visit: www.immunotherapyofcancer.org/about/edboard.
Waived Article Processing Charges for SITC Members
As a thank you to our members, SITC is offering waived article processing charges throughout 2014 (a $2,400 USD savings). For your membership code, please contact the SITC office at +1(414) 271-2456. |
.gif)
.gif)
